Efficacy of bevacizumab therapy for unresectable malignant glioma: A retrospective analysis

Bevacizumab (BEV), an inhibitor of vascular endothelial growth factor A, has been used for primary and recurrent malignant gliomas in Japan since June, 2013. Previous randomized controlled studies demonstrated that BEV prolonged the progression-free survival, but not the overall survival (OS) of pat...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Mol Clin Oncol
Asıl Yazarlar: Yonezawa, Hajime, Hirano, Hirofumi, Uchida, Hiroyuki, Habu, Mika, Hanaya, Ryosuke, Oyoshi, Tatsuki, Sadamura, Yuko, Hanada, Tomoko, Tokimura, Hiroshi, Moinuddin, Fm, Arita, Kazunori
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: D.A. Spandidos 2017
Konular:
Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5244831/
https://ncbi.nlm.nih.gov/pubmed/28123740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2016.1086
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller